AHCO AdaptHealth Corp. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AHCO Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Devices
Current Price
Live
$10.65
Analyst Target
$13.38
+25.6%
Upside
52W High
$11.63
52W Low
$7.11
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 07, 2026
Market cap
$1.44B
P/E
19.02
ROE
5.5%
Profit margin
2.5%
Debt/Equity
1.17
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
AHCO's Piotroski F-Score of 4/9 indicates weak financial health, falling short of the threshold for stability. The absence of an Altman Z-Score raises concern about potential distress risk, especially given a high debt/equity ratio of 1.17 and a current ratio of 1.08. While the stock trades below its Graham Number ($12.4) and intrinsic value ($9.55), its valuation is undermined by deteriorating earnings quality, persistent negative earnings surprises, and a 27.3% YoY EPS decline. Insider selling activity and a technical trend score of 10/100 further signal bearish sentiment. Despite modest revenue growth, profitability remains weak, with low margins and ROE.
Key Strengths
Trading below Graham Number ($12.4), suggesting potential undervaluation on a defensive basis
Price/Sales of 0.44 indicates low valuation relative to revenue
Positive Q/Q EPS growth of 128.6% in most recent quarter suggests short-term recovery momentum
Debt/Equity of 1.17 is below sector average (2.68), indicating relatively moderate leverage
Recent 6-month price return of +15.9% shows some market re-rating despite long-term underperformance
Key Risks
Piotroski F-Score of 4/9 signals weak financial health and declining operational efficiency
Persistent negative earnings surprises over the last 4 quarters (average -42.54%) indicate poor earnings quality
Insider selling of $0.13M in last 6 months with no buys reflects bearish sentiment from insiders
Current ratio of 1.08 and quick ratio of 0.69 suggest tight liquidity and potential short-term solvency concerns
5-year price performance down 70.2% and 3-year down 48.4% reflect deep market skepticism and structural issues
AI Fair Value Estimate
Based on comprehensive analysis
$9.55
-10.3% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
34
Weak
65
38
30
35
0
AI Verdict
Weak
Key drivers: Low Piotroski F-Score, Negative earnings trends, High insider selling, Poor technical momentum, Weak profitability metrics
Confidence
85%
Value
65/100
Ref P/E, PEG, Graham Number
Positives
- Current price ($10.65) below Graham Number ($12.4)
- Price/Sales of 0.44 is low for healthcare sector
- Price/Book of 0.87 suggests asset-based undervaluation
Watchpoints
- Intrinsic value estimate ($9.55) is below current price, suggesting overvaluation on growth basis
- Forward P/E of 10.71 is misleading due to volatile earnings history
Future
38/100
Ref Growth rates
Positives
- Q/Q EPS growth of +128.6% in most recent quarter
- Revenue growth of 1.80% YoY, slightly positive
Watchpoints
- YoY EPS growth of -27.3% indicates deteriorating profitability
- Forward P/E of 10.71 is not supported by consistent earnings growth
- No PEG ratio available due to unreliable growth projections
Past
30/100
Ref Historical trends
Positives
- Historical EPS beat in 2024 Q1 and Q2 with surprise of +163.1% and +167.2%
- Some strong quarters in 2021–2023 with positive surprises
Watchpoints
- Last 4 quarters all missed estimates with average surprise of -42.54%
- 5-year price decline of 70.2% reflects long-term underperformance
- Persistent negative earnings trends despite revenue growth
Health
35/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity of 1.17 is below sector average (2.68)
- Current ratio of 1.08 is above 1.0, indicating basic liquidity
Watchpoints
- Piotroski F-Score of 4/9 is below stability threshold (4-6)
- Quick ratio of 0.69 suggests limited short-term liquidity
- No Altman Z-Score available; risk of distress cannot be ruled out
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength score of 0/100 indicates no dividend history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$10.65
Analyst Target
$13.38
Upside/Downside
+25.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AHCO and closest competitors.
Updated 2026-02-06
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AHCO
AdaptHealth Corp.
Primary
|
-70.2% | -48.4% | +10.2% | +15.9% | +1.4% | +6.0% |
|
BCRX
BioCryst Pharmaceuticals, Inc.
Peer
|
-25.9% | -38.3% | -12.2% | -20.6% | -11.8% | +1.9% |
|
ANAB
AnaptysBio, Inc.
Peer
|
+67.4% | +89.8% | +209.3% | +136.5% | +10.0% | +4.9% |
|
ATAI
AtaiBeckley Inc.
Peer
|
-78.7% | +117.3% | +174.8% | +16.2% | -0.9% | +14.0% |
|
AXGN
Axogen, Inc.
Peer
|
+76.4% | +203.1% | +75.6% | +145.6% | +0.6% | +5.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
19.02
Forward P/E
10.71
PEG Ratio
N/A
P/B Ratio
0.87
P/S Ratio
0.44
EV/Revenue
1.0
EV/EBITDA
5.13
Market Cap
$1.44B
Profitability
Profit margins and return metrics
Profit Margin
2.53%
Operating Margin
8.18%
Gross Margin
21.5%
ROE
5.52%
ROA
3.64%
Growth
Revenue and earnings growth rates
Revenue Growth
+1.8%
Earnings Growth
+6.7%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+7.2%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.17
Moderate
Current Ratio
1.08
Good
Quick Ratio
0.69
Poor
Cash/Share
$0.61
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-24
$N/A
2025-11-04
$0.16
-32.3% surprise
2025-08-05
$0.07
-55.0% surprise
2025-05-06
$0.02
-40.4% surprise
Healthcare Sector Comparison
Comparing AHCO against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
P/E Ratio
19.02
This Stock
vs
197.69
Sector Avg
-90.4%
(Discount)
Return on Equity (ROE)
5.52%
This Stock
vs
-56.84%
Sector Avg
-109.7%
(Below Avg)
Profit Margin
2.53%
This Stock
vs
-20.8%
Sector Avg
-112.1%
(Weaker)
Debt to Equity
1.17
This Stock
vs
2.68
Sector Avg
-56.3%
(Less Debt)
Revenue Growth
1.8%
This Stock
vs
61.93%
Sector Avg
-97.1%
(Slower)
Current Ratio
1.08
This Stock
vs
3.47
Sector Avg
-68.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AHCO
AdaptHealth Corp.
|
BEARISH | $1.44B | 19.02 | 5.5% | 2.5% | $10.65 | |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
NEUTRAL | $1.43B | - | -% | -1.5% | $6.79 | |
|
ANAB
AnaptysBio, Inc.
|
BULLISH | $1.39B | - | -308.0% | -49.9% | $49.73 | |
|
ATAI
AtaiBeckley Inc.
|
BEARISH | $1.51B | - | -100.8% | -% | $4.15 | |
|
AXGN
Axogen, Inc.
|
NEUTRAL | $1.51B | - | -1.9% | -1.0% | $32.83 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-30 | FOSTER SUZANNE | Chief Executive Officer | Stock Award | 329,449 | - |
| 2026-01-30 | CLEMENS JASON A | Chief Financial Officer | Stock Award | 126,899 | - |
| 2026-01-30 | ARCHBOLD CHRISTINE E. | Officer | Stock Award | 32,213 | - |
| 2026-01-30 | BARNHART TOBY SCOTT | Chief Operating Officer | Stock Award | 68,330 | - |
| 2026-01-30 | SCHUSTER RUSSELL E. III | Officer | Stock Award | 48,807 | - |
| 2026-01-30 | MCFADDEN DANIEL EDWARD | Officer | Stock Award | 29,284 | - |
| 2026-01-09 | BELINFANTI GREGORY A | Director | Stock Award | 11,776 | - |
| 2026-01-09 | LUNDBERG THEODORE B. | Director | Stock Award | 13,740 | - |
| 2025-12-04 | WILLIAMS DAVID SOLOMON III | Director | Sale | 5,000 | $47,150 |
| 2025-08-22 | WILLIAMS DAVID SOLOMON III | Director | Sale | 8,200 | $79,786 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
8 analysts
Canaccord Genuity
2025-11-06
Buy
Buy
Past News Coverage
Recent headlines mentioning AHCO from our newsroom.
Newest → oldest
No matching news yet.